On November 21, 2025, the results of the 2025 academician elections for China's two highest academic institutions—the Chinese Academy of Engineering (CAE) and the Chinese Academy of Sciences (CAS)—were announced. The CAE elected 100 new academicians, and the CAS elected 95 new academicians. Academician status in the CAE and CAS represents the highest lifelong honor in the fields of engineering and science in China. New academicians are elected every two years through a rigorous multi‑round selection process.
Professor Ji Jiafu, Director of the Department of Gastrointestinal Surgery at Peking University Cancer Hospital (also known as Beijing Cancer Hospital), and Co-Editor-in-Chief of Translational Gastroenterology and Hepatology, has been elected as an Academician of the Chinese Academy of Engineering.
Prof. Prof. Jia-fu Ji, MD, FACS, received his master degree from Beijing Medical University (now the Peking University Health Science Center) in 1990. He later received a Doctor of Oncology degree from Cardiff University in the United Kingdom in 2015 and a Doctor of Public Health degree from Johns Hopkins University in the United States in 2022. Since 1990, he has been working in the Department of Surgery at Peking University Cancer Hospital, during which he conducted postdoctoral research in oncology at Stanford University in the United States. He previously served as the Director of Peking University Cancer Hospital. Currently, he holds the positions of Director of the Department of Surgery at Peking University Cancer Hospital, Chief Expert of the Gastrointestinal Cancer Center, Director of the Peking University Cancer Research Center, Deputy Director of the National Key Laboratory of Integrated Prevention and Treatment of Digestive System Tumors, and Member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences.
Prof. Ji Jiafu has long focused on the clinical diagnosis and treatment as well as cutting-edge research of gastrointestinal tumors such as gastric cancer. He spearheaded the establishment of a comprehensive diagnosis and treatment system for gastric cancer centered around surgery, and through a series of pioneering studies, he has set multiple new international standards for the diagnosis and treatment of gastric cancer. By creating a new system for precision surgery in gastric cancer, establishing a new model for perioperative comprehensive treatment, and formulating new strategies for immunotherapy, he has significantly improved the survival rates of gastric cancer patients. His work has gained recognition both domestically and internationally. He served as President of the International Gastric Cancer Association and for the first time organized the International Gastric Cancer Congress in China. As the principal investigator, he received one National Science and Technology Progress Award (Second Prize) and four provincial/ministerial-level first prizes. He has also been honored with the Guanghua Engineering Science and Technology Award, the Ho Leung Ho Lee Foundation Prize for Scientific and Technological Progress, and the Wu Jieping-Paul Janssen Award for Medical and Pharmaceutical Sciences. He has been recognized as a National Health Commission Young and Middle-aged Expert with Outstanding Contributions and selected for programs such as the "Beijing Scholar" initiative.